Phenex AG provides compound profiling services to BayerSchering Pharma AG

Ludwigshafen, Germany, February 8th, 2007

“We are very proud to have won Bayer Schering Pharma AG as a customer for our Nuclear Receptor technology platform.“
– Dr. Claus Kremoser –
CEO of Phenex

Phenex Pharmaceuticals AG announced today that it provides services in compound and cofactor profiling at certain Nuclear Receptor drug targets for Bayer Schering Pharma AG. Nuclear Receptors, such as the steroid receptors, are important drug targets which are very relevant for the development of contraceptives, other women’s or men’s health medicines, and certain cancer or cardiovascular drugs. Phenex has built a special technology platform around Nuclear Receptors, called SNuRM®, that allows to analyze differences between novel drug candidates regarding their potential to elicit wanted or unwanted effects. Phenex and Bayer Schering Pharma AG have now entered into a fee-for-service collaboration to evaluate and use this SNuRM® technology from Phenex in their drug discovery research.

„We are very proud to have won Bayer Schering Pharma AG as a customer for our Nuclear Receptor technology platform,“ says Dr. Claus Kremoser, CEO of Phenex. He continues: “With this collaboration we not only expand our revenues and customer base in Europe. Moreover, working together with such experts in steroid receptor drug discovery validates our Nuclear Receptor platform and will help us to further improve the practical utility of this technology.”

About Phenex´ SNuRM® technology:

The SNuRM®-Technology combines automated protein interaction analysis with Nuclear Receptor specific gene expression analysis. Nuclear Receptors are generally known as excellent drug targets. With some Nuclear Receptors the striking phenomenon can be observed that the same ligand at the same receptor can be stimulatory as well as inhibitory, depending on the chemical nature of the ligand and the tissue environment. Classical Nuclear Receptor targeted drugs tend to yield a good efficacy for their main indication but can potentially lead to adverse effects (e.g. cortisol as an antiinflammatory glucocorticoid). Phenex´ SNuRM®-Technology assesses the molecular effects of different compounds at the targeted Nuclear Receptor and thereby contributes important information to the design of novel selective drugs with much less adverse effects.

Contact

Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com

About Phenex Pharmaceuticals AG

Phenex is a privately held drug discovery and development company headquartered in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.